Evaluation of the Engineering Company΄s Performance

Import 05/08/2014Cílem této diplomové práce je analyzovat a zhodnotit výkonnost podniku LUCCO a.s. pomocí vybraných metod a na základě zjištěných výsledků navrhnout doporučení pro případné zlepšení.V teoretické části jsou popsány pojmy výkonnost a jednotlivé metody tj. SWOT analýza, BSC, a bonitní a bankrotní modely, které se aplikují v praktické části. V praktické části diplomové práce se nachází charakteristika podniku LUCCO a.s. a následně zde budou zpracovány a popsány jednotlivé metody a okomentována výsledná zjištění. V poslední části jsou doporučení pro zlepšení výkonnosti podniku.The aim of this thesis is to analyze and evaluate the performance of the company as LUCCO using selected methods and based on the findings propose recommendations for possible zlepšení.V theoretical part describes the concepts and the performance of each method, ie, SWOT analysis, BSC, and value and bankruptcy models that are applied in the practical part. In the practical part of the thesis is characteristic of the enterprise as LUCCO and then there will be processed and described various methods and discussed the resulting findings. In the last section are recommendations for improving business performance.152 - Katedra podnikohospodářskávelmi dobř

Abundance and α-diversity comparison of bacteriome and mycobiome between PMA-pretreated and untreated samples.

<p>Abundance and α-diversity comparison of bacteriome and mycobiome between PMA-pretreated and untreated samples.</p

Effect of PMA on the composition of mycobiome of each sample.

<p><b>(A)</b>: Relative abundance of fungal genera of each sample (“yes” or “no” indicates the samples with or without PMA-pretreatment). <b>(B)</b>: PCA plot of the first two components of mycobiome of samples with and without PMA-pretreatment. Each marker represents treatment conditions (filled triangle symbols PMA-treated samples, filled square symbols untreated samples). Each color represents a given sputum sample (G040.III: dark blue; G088.II: chartreuse; G088.III: dark green; G172.I: yellow; G172.II: orange; G172.III: dark orange; G014.II: dark grey; G014.III: black; G176.II: firebrick; G176.III: dark red).</p

Venn diagram representing number of shared and specific bacterial (A) and fungal (B) genera between PMA-treated and untreated samples.

<p>In each case, the first 5 most prevalent genera are listed.</p

Median density (for 27 samples from 18 patients) of <i>P. aeruginosa</i> cells/ml sputum at hospitalization days 1, 8 and 15, as determined by the three quantification techniques, <i>i.e.</i> culture, qPCR and PMA-qPCR.

<p>*  =  statistically significant (p<0.05).</p

Median values (ranges) for 27 episodes of hospitalization (18 patients) for the clinical parameters obtained at days 1, 8 and 15 of hospitalization.

<p>Significant change in comparison with day 1, <i>p<0.05</i> (Wilcoxon).</p

<i>p-values</i> and <i>r-values</i> of similarity analysis (one-way ANOSIM) of the bacterial and fungal OTU data.

<p><i>p-values</i> and <i>r-values</i> of similarity analysis (one-way ANOSIM) of the bacterial and fungal OTU data.</p

Abundance and α-diversity comparison of bacteriome and mycobiome between PMA-pretreated and untreated samples.

<p>Abundance and α-diversity comparison of bacteriome and mycobiome between PMA-pretreated and untreated samples.</p

Primers used in this study.

<p>Primers used in this study.</p

Comparison of the enumeration of <i>P</i>. <i>aeruginosa</i> cells between cultures and qPCRs of PMA-treated and untreated sputum samples.

<p>Comparison of the enumeration of <i>P</i>. <i>aeruginosa</i> cells between cultures and qPCRs of PMA-treated and untreated sputum samples.</p